Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$28.61 -0.7%	$30.01	$22.90 ▼ $36.45	$4.75B	0.47	1.72 million shs	1.39 million shs
ARVN Arvinas	$7.36 -2.4%	$7.40	$5.90 ▼ $34.11	$550.35M	2.19	1.44 million shs	1.39 million shs
KRTX Karuna Therapeutics	$329.83	$327.01	$158.38 ▼ $329.99	$12.58B	1.18	832,048 shs	5 shs
PCRX Pacira BioSciences	$23.90 +1.8%	$25.36	$11.16 ▼ $29.33	$1.09B	0.52	948,557 shs	1.06 million shs
RETA Reata Pharmaceuticals	$172.36	$171.30	$21.83 ▼ $172.46	$6.58B	1.42	1.09 million shs	N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	-0.69%	-2.22%	-7.26%	-12.05%	+18.71%
ARVN Arvinas	-2.39%	-0.54%	+1.80%	+4.69%	-72.35%
KRTX Karuna Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PCRX Pacira BioSciences	+1.79%	-3.40%	-7.33%	-0.71%	-16.46%
RETA Reata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.9055 of 5 stars	4.4	3.0	0.0	4.2	2.8	2.5	1.9
ARVN Arvinas	3.442 of 5 stars	4.3	2.0	0.0	0.0	1.6	2.5	1.3
KRTX Karuna Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	3.4943 of 5 stars	2.2	2.0	0.0	3.9	2.7	2.5	0.6
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.00	39.81% Upside
ARVN Arvinas	2.55	Moderate Buy	$20.29	175.67% Upside
KRTX Karuna Therapeutics	0.00	N/A	N/A	N/A
PCRX Pacira BioSciences	2.33	Hold	$26.44	10.65% Upside
RETA Reata Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KRTX, ARVN, ALKS, PCRX, and RETA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/13/2025	ALKS Alkermes	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
5/9/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $30.00
5/5/2025	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.50
5/5/2025	ARVN Arvinas	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $10.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.03	$2.63 per share	10.87	$9.05 per share	3.16
ARVN Arvinas	$426.90M	1.26	N/A	N/A	$8.17 per share	0.90
KRTX Karuna Therapeutics	$654K	19,239.07	N/A	N/A	$33.24 per share	9.92
PCRX Pacira BioSciences	$700.97M	1.58	$4.39 per share	5.44	$16.86 per share	1.42
RETA Reata Pharmaceuticals	$23.48M	280.05	N/A	N/A	($1.79) per share	-96.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.69	20.88	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
KRTX Karuna Therapeutics	-$433.68M	-$11.72	N/A	N/A	N/A	N/A	-31.63%	-30.38%	N/A
PCRX Pacira BioSciences	-$99.56M	-$2.28	N/A	9.30	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)
RETA Reata Pharmaceuticals	-$311.90M	N/A	0.00	N/A	N/A	N/A	-922.50%	-73.39%	N/A

Latest KRTX, ARVN, ALKS, PCRX, and RETA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
7/29/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	N/A	N/A	N/A	$183.11 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
KRTX Karuna Therapeutics	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
ARVN Arvinas	N/A	4.58	4.58
KRTX Karuna Therapeutics	N/A	19.31	19.31
PCRX Pacira BioSciences	0.48	2.41	1.99
RETA Reata Pharmaceuticals	0.84	3.21	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
ARVN Arvinas	95.19%
KRTX Karuna Therapeutics	N/A
PCRX Pacira BioSciences	99.73%
RETA Reata Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
ARVN Arvinas	4.73%
KRTX Karuna Therapeutics	13.20%
PCRX Pacira BioSciences	6.40%
RETA Reata Pharmaceuticals	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
KRTX Karuna Therapeutics	339	38.15 million	33.16 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable
RETA Reata Pharmaceuticals	321	38.15 million	27.93 million	Optionable

KRTX, ARVN, ALKS, PCRX, and RETA Headlines

Recent News About These Companies

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

February 12, 2025 | fiercebiotech.comF

Arbe Robotics (NASDAQ:ARBE) Stock Quotes, Forecast and News Summary

November 1, 2024 | benzinga.com

What to Know: How Israel Could Retaliate Against Iran

October 27, 2024 | nytimes.com

Reta Hendrickson

September 11, 2024 | newsandsentinel.comN

Reata rockets on data for Nrf2 drug reacquired from AbbVie

August 8, 2024 | pharmaphorum.comP

Lazard hires veteran healthcare dealmaker Colocci as vice chairman

May 9, 2024 | investing.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 18, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 16, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 11, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 9, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 4, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 2, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 28, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 26, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 21, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 19, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 14, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 12, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 7, 2024 | accesswire.comA

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 5, 2024 | accesswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
By Gabriel Osorio-Mazilli | June 16, 2025
View China Market Movers: MCHI, PDD, BIDU Show Bullish Trends
Tariff Talks Advance, What Taiwan Semiconductor Can Deliver
By Gabriel Osorio-Mazilli | June 16, 2025
View Tariff Talks Advance, What Taiwan Semiconductor Can Deliver

KRTX, ARVN, ALKS, PCRX, and RETA Company Descriptions

Alkermes NASDAQ:ALKS

$28.61 -0.20 (-0.69%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$28.76 +0.15 (+0.51%)

As of 09:15 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Arvinas NASDAQ:ARVN

$7.36 -0.18 (-2.39%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$7.42 +0.06 (+0.88%)

As of 08:57 AM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Pacira BioSciences NASDAQ:PCRX

$23.90 +0.42 (+1.79%)

Closing price 06/30/2025 04:00 PM Eastern

Extended Trading

$23.88 -0.02 (-0.08%)

As of 09:16 AM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time